drugset
drugset / Trial / NCT02938494

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

NCT02938494 ↗

Phase 2 Completed 210 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris

Timeline

Start
2015-11
Primary completion
2016-07
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.045 % —
Subject Tazarotene Small molecule 0.1 % —

Indications

acne